Sonnet BioTherapeutics Holdings, Inc.
SONN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.01 | 0.00 | 0.03 |
| FCF Yield | -35.78% | -47.03% | -98.54% | -72.87% |
| EV / EBITDA | -1.24 | -0.78 | 0.64 | -1.37 |
| Quality | ||||
| ROIC | 130.86% | -561.89% | -72.33% | 894.22% |
| Gross Margin | 0.00% | 0.00% | -88.61% | 0.00% |
| Cash Conversion Ratio | 0.47 | 0.71 | 0.92 | 1.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 79.36% | 71.42% | 57.20% | -62.38% |
| Free Cash Flow Growth | 28.82% | 15.08% | 8.20% | -2.87% |
| Safety | ||||
| Net Debt / EBITDA | 0.07 | 0.47 | 1.68 | 0.01 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -15,231.17 | -7,108.97 | -6,590.66 | -9,095.04 |